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ABSTRACT
The electrooxidative behavior of pravastatin (PRV) in aqueous media was studied by square-wave voltammetry at a glassy-
carbon electrode (GCE) and at a screen-printed carbon electrode (SPCE). Maximum peak current intensities in a pH 5.0 buffer were 
obtained at +1.3 V vs. AgCl/Ag and +1.0 V vs. Ag for the GCE and SPCE surface respectively. Validation of the developed method-
ologies revealed good performance characteristics and confirmed their applicability to the quantification of PRV in pharmaceutical 
products, without significant sample pretreatment. A comparative analysis between the two electrode types showed that SPCEs are 
preferred as an electrode surface because of their higher sensitivity and the elimination of the need to clean the electrode’s surface 
for its renewal, which frequently is, if not always, the rate-limiting step in voltammetric analysis.
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INTRODUCTION
Lipid-modifying interventions have been shown to 
decrease the risk of coronary heart disease both in patients 
with hypercholesterolaemia and in those with relatively 
normal levels of low-density lipoprotein cholesterol(1).
Pravastatin (Figure 1) belongs to the class of the 
most widely used lipid-lowering drugs, statins. It is a 
water-soluble cholesterol-reducing agent, which acts 
by inhibiting 3-hydroxy-3-methylglutaryl-coenzyme A 
(HMG-CoA) reductase. The enzyme catalyses the conver-
sion of HMG-CoA to mevalonate, the rate-limiting step 
in cholesterol synthesis(2). Competitive inhibition of this 
enzyme by the statins decreases hepatocyte cholesterol 
synthesis(1).
A large number of high-performance liquid chro-
matographic (HPLC) procedures have been developed 
for PRV determination in a variety of matrices, such as 
pharmaceuticals, serum, plasma, urine and sewage. The 
most recently used methods are based on HPLC coupled 
with ultraviolet/diode array(3-7) and mass(5,8-15) detectors. 
Recently, a visible spectrophotometric method has also 
been described(16).
Prior to the present work, there was only one electro-
analytical study on PRV that had been published(17). The 
study focused on the reductive and adsorptive behaviours 
of PRV at a hanging mercury-drop electrode. No study on 
the oxidative behaviour of PRV has been published to date.
Within the field of electroanalytical science, various 
kinds of disposable electrochemical sensors based on 
SPCEs are becoming increasingly important, as they help 
in the development of on-site monitoring for clinical, 
environmental, biological, food and industrial analysis. 
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Features such as design flexibility, good reproducibility, 
low reagent consumption and particularly the possibility 
of mass production, make them an attractive alternative 
for sensor building materials(18).
In the present work, the oxidation of PRV at a 
glassy-carbon electrode (GCE) and at a screen-printed 
carbon electrode (SPCE) was studied with the use of 
square-wave voltammetry (SWV). Two different methods 
were developed and successfully applied to the quanti-
fication of PRV in a pharmaceutical product of current 
therapeutic use.
MATERIALS AND METHODS
Pravastatin sodium standard was purchased 
from Sigma-Aldrich and used without further puri-
fication. The standard was stored at 4°C. Stock solu-
tions were obtained by dissolving adequately weighed 
amounts of the standard in deionised water (conductivity 
< 0.1 µS cm-1). To obtain the desired concentration for 
analysis, the stock solutions were diluted with electro-
lyte solution [Britton-Robinson buffer (I = 0.3 mol/L), pH 
5.0]. All other chemicals were of analytical grade.
Voltammetric measurements were performed with an 
Autolab PGSTAT12 potentiostat (Metrohm-EcoChemie, 
Utrecht, The Netherlands), controlled by a computer 
installed with GPES 4.9 software (Metrohm-EcoChemie 
Utrecht, The Netherlands). When using the GCE, the 
potentiostat was coupled with a Metrohm 663 VA stand 
containing a three-electrode cell (Metrohm). The cell 
consisted of a glassy-carbon working electrode (d = 2 mm), 
an Ag/AgCl/KCl (3 mol/L) reference electrode and a glassy-
carbon auxiliary electrode. Commercially available SPCEs 
(ref. 110 - DropSens, Oviedo, Spain) were also used. These 
electrodes consisted of a carbon working disk electrode 
(d = 4 mm), an auxiliary carbon electrode and a silver 
pseudo-reference electrode, all printed on the same alumina 
strip. An insulating area served to delimit the working 
area and electrical contacts. With these electrodes, the 
experimental set-up was similar to that mentioned above, 
replacing the electrode-cell with an adaptor for the SPCEs 
(DSC - DropSens, Oviedo, Spain).
Between measurements, SPCEs were replaced while 
the surface of the GCE had to be cleaned. The cleaning 
procedure involved polishing the electrode surface on an 
abrasive cloth with Al2O3 (0.3 mm, BDH chemicals). The 
electrodes were then rinsed with deionised water and dried.
For assays using the GCE, the background voltam-
mogram was obtained by introducing 10.00 mL or 
15.00 mL of supporting electrolyte into a voltammetric 
cell. Before analysis, deoxygenation was performed by 
purging the electrolyte with oxygen-free nitrogen for 
300 s, with stirring. After the deoxygenation process, 
the stirring was stopped and the background voltam-
mogram was recorded. The electrode was then cleaned 
and the required amount of PRV standard solution was 
added to the cell. The procedure was repeated using a 
10-s nitrogen-purge between measurements. For SPCEs, 
voltammetric measurements were performed by placing a 
50-µL drop of the analyte solution over the exposed area. 
To record the background signal, the analyte solution was 
replaced with the electrolyte. In both cases, the square-
wave voltammograms were obtained by applying a 
potential scan in the positive direction.
To evaluate the precision of using the GCE for the 
analysis of PRV in terms of  repeatability and interme-
diate precision, PRV solutions of 8.0 × 10-5, 1.0 × 10-4 
and 1.2 × 10-4 mol/L were analysed five times per day 
over three consecutive days. For the SPCE, the same 
approach was used by analysing PRV solutions of 1.0 × 
10-4, 3.0 × 10-4 and 7.5 × 10-4 mol/L.
In order to evaluate the selectivity and accuracy of 
the procedure for the analysis of PRV in Pravastatin Alter 
(Alter S.A., 10 mg PRV/tablet, gross weight = 0.1 g), five 
tablets were weighed and finely powdered. About 0.108 g 
 of the resulting mixture was transferred to a 10.00-mL 
volumetric flask and water was added. The flask was 
then placed in an ultrasonic bath for 15 min to extract 
PRV from the matrix. For the method using the GCE, a 
442.5-µL aliquot of the resulting suspension was placed 
in 10.00 mL of supporting electrolyte contained in the 
voltammetric cell and analysed. Subsequently, three 
standard additions were made (5.0 × 10-5, 1.00 × 10-4 and 
1.50 × 10-4 mol/L) and the voltammetric scan was applied 
after each addition. Selectivity was evaluated by recovery 
studies and comparing the slope of an external standard 
calibration curve with the slope of the standard addition 
curve. For the method using the SPCE, five 105.9-µL 
aliquots of the suspension were placed in five 5.00-mL 
volumetric flasks and standard additions of 0, 5.00 × 
10-5, 2.50 × 10-4, 4.50 × 10-4 and 7.00 × 10-4 mol/L were 
made. The resulting solutions were then analysed by the 
developed SWV procedure. Selectivity was evaluated by 
comparing the slope of an external standard calibration 
curve with the slope of the standard addition curve.
For the quantification of PRV in Pravastatin Alter, 
five tablets were weighed and finely powdered. About 
0.108 g of the resulting mixture was transferred to 
50.00-mL (GCE) or 10.00-mL (SPCE) volumetric flasks 
and placed in an ultrasonic bath for 15 min in order to 
extract PRV from the matrix. The resulting suspension 
was then diluted in the voltammetric cell (GCE) or in 
5.00-mL volumetric flasks (SPCE) with supporting elec-
trolyte to obtain the desired PRV concentrations (within 
the linear ranges) for analysis. Quantification of PRV was 
carried out by the external calibration method.
RESULTS AND DISCUSSION
I. Optimization
The optimization of the experimental conditions was 
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performed using the glassy-carbon electrode.
High-frequency square-wave voltammetry was used 
to study the electrochemical oxidation of PRV at the 
glassy-carbon electrode. The electrochemical behavior 
of PRV (1.0 × 10-4 mol/L) was verified over the pH 
range 1.40 - 11.70, using Britton-Robinson buffers as 
supporting electrolytes. The results showed that PRV 
gave rise to one anodic peak over the whole pH range 
investigated. At a pH value of 5.0, the highest and best-
defined oxidation peak was obtained at approximately 
+1.3 V vs. AgCl/Ag.
Since SWV was used for the determination of PRV 
in a pharmaceutical dosage form, it was necessary to 
determine the most adequate SWV parameters in order to 
obtain the best peak characteristics for PRV analysis. The 
frequency ( f ), pulse step (∆Es) and pulse amplitude (∆Ep) 
were optimized using a 1.0 × 10-4 mol/L PRV solution in 
a Britton-Robinson buffer (pH = 5.0). The influence of f 
was studied over a range of 10-100 Hz. The peak current 
intensity (ip) increased linearly until 90 Hz (ip = 0.016 × 
f + 0.86; ip - µA, f - Hz). A less significant increase of ip 
was observed after this value. Hence, an f of 90 Hz was 
adopted in subsequent experiments. Variation of DEs 
from 1 to 10 mV and of ∆Ep from 5 to 50 mV resulted 
in a marked increased of ip up to 5.25 mV (ip = 0.53 × 
∆Es + 1.3; ip - µA, ∆Es - mV) and 40 mV (ip = 0.12 × ∆Ep 
+ 0.52; ip - µA, ∆Ep - mV) respectively, after which the 
ip values remained constant. These optimized conditions 
were used in all the subsequent studies.
II. Validation
(I) Glassy-Carbon Electrode
A linear relationship between peak current inten-
sity and PRV concentration was obtained for the interval 
between 6.0 × 10-5 and 9.2 × 10-4 mol/L. Typical voltam-
mograms of PRV concentrations within this range are 
shown in Figure 2.
Limits of detection (LOD) and quantification (LOQ)
(19) as well as other calibration plot characteristics are 
given in Table 1. The results of the precision studies 
(Table 2) confirmed that the method was precise.
To verify whether excipients in the Pravastatin Alter 
tablets interfered with the analysis, recovery and selec-
tivity studies were performed. Recovery values between 
97.9% and 102.3% were obtained, confirming that the 
method was accurate and that excipients did not inter-
fere significantly with the analysis. In addition, the ratio 
between the slope of the external standard calibration 
Table 1. Analytical data from the calibration plot in the determina-
tion of PRV by SWV
Property GCE SPCE
Linear range (µmol/L) 60 - 920 50 - 1000
Correlation coefficient 0.999 (n = 8) 0.999 (n = 6)
Slope (mA L mol-1) 5.43 82
Standard error slope (mA L mol-1) 0.04 1.3
Intercept (µA) 0.20 8.7
Standard error intercept (µA) 0.02 0.8
LOD (µmol/L) 11 30
LOQ (µmol/L) 37 101
Table 2. Results from the evaluation of precision*
Electrode
Repeatability** 
(RSD %, n = 5)
Intermediate Precision** 
(RSD %, n = 3)
GCE
1.4 (0.8)
0.9 (1.0)
5.3 (1.2)
1.0 (0.8)
3.8 (1.0)
3.0 (1.2)
SPCE
4.2 (1.0)
4.4 (3.0)
1.3 (7.5)
3.5 (1.0)
6.1 (3.0)
0.6 (7.5)
* Concentrations in 10-4 mol/L are given in parentheses.
** RSD: Relative standard deviation
Figure 2. Square-wave voltammograms of PRV in the linear range by 
GCE. [PRV] (× 10-4 mol/L): 1.00, 1.50, 2.00, 2.50 and 3.00 ( f : 90 Hz; 
DEs: 5.25 mV; DEp: 40 mV). (i/μA: current intensity/micro-ampere; 
E/V: applied potential/volt).
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plot and the slope of a standard addition curve was found 
to be 1.1, indicating that the method was selective for the 
determination of PRV in this sample.
(II) Screen-Printed Carbon Electrodes
With the previously optimized SWV parameters 
using the glassy-carbon electrode, the oxidation peak 
of PRV was obtained at about +1.0 V vs. Ag. Using the 
previously optimized SWV parameters and analytical 
conditions, validation of the SWV procedure for PRV 
analysis was repeated using SPCEs. Table 1 lists the 
characteristics of the calibration curve and the respective 
LOD and LOQ values calculated using the curve. Typical 
voltammograms of PRV concentrations within the linear 
range are shown in Figure 3.
The results from the evaluation of precision are 
reported in Table 2, indicating that the method was 
precise. A 1.1 ratio between the slope of an external stan-
dard calibration plot and the slope of a standard addition 
curve confirmed the method’s selectivity.
III. Application
In the application of the SWV method to the quantifi-
cation of PRV in the pharmaceutical product, Pravastatin 
Alter, the labeled values (10 mg per tablet) were in good 
agreement with the obtained results: 9.97 ± 1.3 mg/tablet 
(n = 3) using the SPCE and 9.78 ± 0.84 mg/tablet (n = 3) 
using the GCE.
CONCLUSIONS
The present study showed that both electrode types 
can be successfully applied to the quantification of PRV 
in a pharmaceutical product. No significant differences 
were found in terms of detection limits, precision and 
accuracy. Both methods provided simple, sensitive, accu-
rate, selective, fast and low cost quantifications of PRV in 
pharmaceutical dosage forms.
Besides the better sensitivity of the SPCE, which is 
probably due to the difference in the active area of the 
electrode, SPCEs have another important advantage over 
the GCE - The use of SPCEs eliminated the need to clean 
the electrode’s surface for its renewal, which frequently 
is, if not always, the rate-limiting step in voltammetric 
analysis.
When compared with published non-chromato-
graphic methods for pravastatin analysis in pharmaceu-
ticals, the obtained linear ranges and limits of detection 
were in the same order of magnitude. Although the limits 
of detection of the developed methods were 2 to 4 orders 
of magnitude higher than those obtained with most of 
the published chromatographic methods, they were suffi-
ciently low for the proposed application.
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